Core Viewpoint - The complaint against CTO Realty Growth alleges violations of federal securities laws, including misleading statements about the sustainability of dividends and the true profitability of its properties, leading to an overstatement of the company's financial prospects [2][3]. Group 1: Allegations and Financial Practices - The complaint claims that CTO's dividends were less sustainable than represented, and the company used deceptive practices to inflate its Adjusted Funds From Operations (AFFO) [2]. - Wolfpack Research's report criticized CTO for not generating sufficient cash to cover recurring capital expenditures and dividends since its conversion to a REIT in 2021, relying instead on share dilution [3]. - The report highlighted that CTO increased its shares outstanding by 70% since December 2022 to cover a $38 million dividend shortfall from 2021 to 2024, and employed a manipulative definition of AFFO that excluded recurring capital expenditures [3]. Group 2: Financial Position and Market Reaction - As of the report, CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with additional planned capital expenditures of approximately $12 million [3]. - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98 per share, or 5.42%, closing at $17.10 per share on June 25, 2025 [4].

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].

Core Viewpoint - The U.S. Department of Justice has filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging illegal kickbacks related to Medicare Advantage plans, leading to a significant drop in SelectQuote's stock price [2]. Group 1: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against SelectQuote on behalf of its stockholders for possible violations of federal securities laws and unlawful business practices [1]. - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. Group 2: Stock Market Impact - Following the announcement of the DOJ lawsuit, SelectQuote's stock price decreased by $0.61 per share, representing a 19.24% decline, closing at $2.56 per share on May 1, 2025 [2].